Protalix BioTherapeutics (AMEX:PLX) released first-quarter financial results and hosted an earnings call on Wednesday.
Read the complete transcript below
Benzinga APIs provide real-time access to earnings call transcripts and financial data. Visit https://www.benzinga.com/apis/ to learn more. View the webcast at https://viavid.
Summary Protalix BioTherapeutics reported a $25 million milestone payment from Chiesi due to European Commission approval of a new dosing regimen for El Fabrio, ending the quarter with $51 million in cash. The company reaffirmed its 2026 revenue guidance of $78 to $83 million, with key revenue drivers being El Fabrio and PRX115’s Phase 2 study and ongoing partnerships. The company plans to capture 15-20% of the global Fabry market by 2031, with strategic focus on expanding El Fabrio’s presence in Europe and advancing PRX115 for uncontrolled gout.